A Proposed Rule by the Food and Drug Administration on 07/15/2014 https://s3.amazonaws.com/public-inspection.federalregister.gov/2014-16374.pdf
Leggi
European Medicines Agency, 25/07/2014 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002647/smops/Positive/human_smop_000714.jsp&mid=WC0b01ac058001d127
Leggi
Jan. 8, 2014 FDA approves Farxiga (dapaglifozin) to treat type 2 diabetes http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm380829.htm
Leggi
http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002647/WC500170171.pdf
Leggi
For Immediate Release: Jan. 17, 2014 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm382100.htm
Leggi
http://www.surgeongeneral.gov/library/reports/50-years-of-progress/index.html
Leggi
Includes certain products containing undeclared active pharmaceutical ingredients FDA NEWS RELEASE July 23, 2013 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm362012.htm
Leggi
No new concerns for GLP-1 therapies identified on the basis of available evidence. 26/07/2013 EMA Press release http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001856.jsp&mid=WC0b01ac058004d5c1
Leggi
FDA Safety [Posted 08/15/2013] http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm365302.htm
Leggi
01/31/2014 - Drug Safety Communication - FDA http://www.fda.gov/Drugs/DrugSafety/ucm383904.htm
Leggi
